{"schema_version":"1.0","type":"article","title":"減重手術後，吃飯竟可能昏倒？一款新藥讓 Amylyx 暴漲 64%！","url":"https://drugnews.com.tw/articles/2026-08-30-amylyx-avexitide-pbh-phase3.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-30-amylyx-avexitide-pbh-phase3.md","lang":"zh-Hant","date":"2026-08-30","publish_at":"2026-08-30T08:00:13+08:00","updated_at":"2026-08-30","category":"基本面系列","topic":"基本面系列","tags":["Amylyx","avexitide","GLP-1","減重手術後低血糖","PBH","LUCIDITY","Relyvrio","MBX Biosciences","生技資產交易"],"summary":"Amylyx 的 avexitide 在 LUCIDITY 三期試驗中，讓第二級與第三級低血糖事件合併發生率較安慰劑降低 55%，帶動股價單日上漲約 64%。本文拆解 PBH 的 GLP-1 機制、三期證據、3,510 萬美元資產收購、5 億美元募資，以及核准與商業化前仍須跨越的關卡。","key_points":[],"facts":[],"sections":["01｜為什麼有人減重手術成功，吃完飯卻可能昏倒？","02｜78 人的三期，為什麼能讓市場如此興奮？","03｜真正反轉的，是 Amylyx 自己的命運","04｜64% 的股價之外，公司立刻做了另一件事","05｜距離上市，還有三道門","06｜每週一針曾驗證概念，卻沒有形成持續競爭","07｜投資人現在要算的，不只是成功機率","結語｜真正的翻身，不在 64% 那一天","主要資料來源"],"references":[],"images":[{"alt":"Amylyx 從撤市谷底，到 GLP-1 對跖點三期成功","url":"https://drugnews.com.tw/assets/articles/amylyx-avexitide-pbh-phase3/01_%E5%B0%81%E9%9D%A2_GLP1%E5%B0%8D%E8%B7%96%E9%BB%9E_%E8%82%A1%E5%83%B9%E6%9A%B4%E6%BC%B264.png"},{"alt":"PBH 機制：GLP-1 訊號過強，胰島素煞車踩過頭","url":"https://drugnews.com.tw/assets/articles/amylyx-avexitide-pbh-phase3/02_PBH%E6%A9%9F%E5%88%B6_avexitide%E9%98%BB%E6%96%B7GLP1%E5%8F%97%E9%AB%94.png"},{"alt":"LUCIDITY 三期證據卡：78 人、16 週、事件減少 55%","url":"https://drugnews.com.tw/assets/articles/amylyx-avexitide-pbh-phase3/03_LUCIDITY%E4%B8%89%E6%9C%9F_55percent%E8%88%87%E5%AE%89%E5%85%A8%E6%80%A7.png"},{"alt":"Amylyx 反轉時間線：撤市、抄底、三期、募資與上市關卡","url":"https://drugnews.com.tw/assets/articles/amylyx-avexitide-pbh-phase3/04_3510%E8%90%AC%E7%BE%8E%E5%85%83%E6%8A%84%E5%BA%95_%E5%9B%9B%E9%81%93%E4%B8%8A%E5%B8%82%E9%97%9C%E5%8D%A1.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/amylyx-avexitide-pbh-phase3/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-30）。減重手術後，吃飯竟可能昏倒？一款新藥讓 Amylyx 暴漲 64%！。https://drugnews.com.tw/articles/2026-08-30-amylyx-avexitide-pbh-phase3.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-08-30-amylyx-avexitide-pbh-phase3-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}